AstraZeneca and Sanofi Block Access to 340B Contract Pharmacy Pricing, Novartis Does Not (UPDATED)

In Federal, Pharma Industry, RegulatoryOctober 1, 2020100 Views

AstraZeneca and Sanofi Block Access to 340B Contract Pharmacy Pricing, Novartis Does Not (UPDATED)

(UPDATED Friday Oct. 2, 2020, 4:30 p.m. EDT)

Congressman Grills Novartis Executive About Steps to Limit 340B Discounts

A Republican U.S. congressman from rural central Pennsylvania yesterday questioned the head of drug manufacturer Novartis’ U.S. operations about the company’s plan to put conditions on 340B discounts on its products, during a hearing about Novartis’ and other companies’ “unsustainable drug prices.”

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

AstraZeneca and Sanofi Block Access to 340B Contract Pharmacy Pricing, Novartis Does Not (UPDATED)

AstraZeneca and Sanofi Block Access to 340B Contract Pharmacy Pricing, Novartis Does Not (UPDATED)

Congressman Grills Novartis Executive About Steps to Limit 340B Discounts

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Tom Mirga

AstraZeneca and Sanofi Block Access to 340B Contract Pharmacy Pricing, Novartis Does Not (UPDATED)

AstraZeneca and Sanofi Block Access to 340B Contract Pharmacy Pricing, Novartis Does Not (UPDATED)

Congressman Grills Novartis Executive About Steps to Limit 340B Discounts

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Tom Mirga

Site Footer